Funding Opportunities
Internal and external funding opportunities collected by the CTSI.
CTSI PilotsThe Translational Pilot Program will solicit, review and award pilot grants designed to produce and test novel tools and methods to bridge translational gaps. |
Ignition FundsProviding ignition funding to accelerate progress for clinical and translational research projects. |
Boost AwardsThese $5K pilot awards are granted quarterly to supplement the translational work of community organizations. |
Community Cooperative Agreements$30K designed to build long-term collaboration through research partnerships between community-based organization and Wake Forest investigators. |
Community-Engaged Research FellowshipFinancial support for representatives from community organizations and WF investigators to build a community-engaged research partnership. |
Special Populations Voucher FundsStudies that identify a financial need can request funds from the voucher program to help overcome barriers related to transportation, child care, etc. |
KL2 FundingProving 2-3 years of support for early-career research faculty from Wake Forest. |
Internal
Recurring Funding Opportunities:
- CTSI - Translational Pilot Program Ignition Funds - (Deadline: 12/05/23)
- CTSI - Research Salary Bridge Funding - (Deadline: 01/01/24)
- CTSI - Early Career Salary Support - (Deadline: 01/01/24)
Research Shark Tank
The Clinical and Translational Science Institute is seeking applications for our next “Research Shark Tank” virtual event scheduled for Thursday, December 7th from 9:00AM – 10:30AM. View this short video to learn more! For more information, click here.
2023 Common Deadline Pilots
|
2023 Common Deadline Pilots |
||
|
Center RFA |
Full Application Deadline |
Application Link |
|
2024 Center for Prevention Science in Child and Family Health Pilot |
12/13/23 by 11:59PM, EST |
|
|
12/13/23 by 11:59PM, EST |
||
|
2024 Center on Critical Illness, Injury, and Recovery Research Center Pilot |
12/13/23 by 11:59PM, EST |
|
|
12/13/23 by 11:59PM, EST |
||
Foundation
Interested applicants may contact the Foundations Relations team at foundations@wakehealth.edu.
| Varied | William T. Grant Foundation | Research Grants on Improving the Use of Research Evidence |
$1M | 1/10/2024 |
| Rheumatology | Arthritis National Research Foundation | Early-career Arthritis and Autoimmune Disease Research Grant |
$250,000 | 1/19/2024 |
| Cancer | Lustgarten Foundation | Equity, Accessibility, and Diversity (LEAD) project |
$450,000 | 2/2/2024 |
NIH
- RFA-AG-24-039: Development and Validation of Harmonized Methodologies to Measure NAD+ and Related Metabolites in Clinical Trials (U01 Clinical Trial Required)
- PAR-23-240: Alcohol and Other Substance Use Research Education Programs for Health Professionals (R25 Clinical Trial Not Allowed)
Professional Associations and Societies
Please refer to the individual Program or Funding Opportunity Announcement for deadline information.
- American Cancer Society
- The Triological Society
- American Heart Association
- American Gastroenterological Association
- American Federation for Aging Research
- Alzheimer's Association
- ALS Association
- American Diabetes Association
- Juvenile Diabetes Research Foundation
- Thoracic Surgery Foundation for Research and Education
- Society for Pediatric Dermatology
Other Opportunities
All of Us Research Program
All of Us Research Program Seeks Engagement and Enrollment Partners: The National Institutes of Health's All of Us Research Program has issues a new funding opportunity soliciting proposals to support outreach, community engagement and participant enrollment and retention efforts. The opportunity spans four specific areas of interest, including community, participant and health care provider engagement, enrollment and retention; researcher engagement; Tribal engagement; and integration of participants and advocates in program oversight.
- Proposals will be accepted on an ongoing basis through May 23, 2025
- Read the Full Announcement
NeuroNEXT Grant
The NeuroNEXT Network is designed to efficiently conduct Phase II Clinical Trials. NeuroNEXT Network is now accepting proposals. Applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing a future trial, for biomarker validation studies, or for proof of mechanism clinical studies are encouraged. Successful applicants will be given access to the NeuroNEXT infrastructure to support the efficient implementation of the proposed study at multiple sites and statistical and data management.
If you are interested, please schedule a meeting to discuss your proposal with the NeuroNEXT Study Team.
- Benefits of Partnering with NeuroNEXT
- Applying for a NeuroNEXT Grant
- Contact: Mysha Sissine, Program Manager
Interested applicants should reach out to the Foundation Relations team.
Opportunity: Clinical Innovator Grant
Protocol Concept Deadline: December 1, 2023
Funding: $1M per clinical trial
Eligibility: Candidates must be the Principal Investigator (PI) of the proposed study. CRI has no citizenship restrictions, and research supported by the award may be conducted at medical schools or research centers in the United States or abroad.
Overview: The CRI Clinical Innovator will support novel clinical studies that address areas of high unmet need in cancer and seek mechanistic insights into clinical response with a goal of predictive biomarker discovery. To maximize the impact of each clinical trial, CRI will advise on selected studies in a coordinated effort to optimize clinical trial design and translational studies.
The Clinical Innovator provides funding for clinician‐scientists aiming to launch innovative phase I/II or phase II clinical studies using novel immunotherapies. In addition to the merits of the clinical and scientific rationale, studies will be selected based on their novelty, feasibility and clinical impact. Competitive applications will have a strong focus on yielding mechanistic insights into clinical response and potentials for biomarker discovery and/or validation. CRI will coordinate efforts on selected trials by advising on the following areas: standardizing sample collection, correlative assays, analysis and data sharing, including, if applicable, deposition of immunogenomic data into the CRI iATLAS platform.
Opportunity: Lloyd J. Old STAR Program – Scientists Taking Risks
Deadline: January 15, 2024
Funding: $1.25M over 5 years
Eligibility:
- • The applicant must have an M.D., Ph.D., or M.D./Ph.D. (or equivalent)
- • Applicants must belong to one of the following categories as of July 1 (following the deadline):
- - Tenure‐track assistant professor with a minimum of 3 years in this position (for Jan. 15, 2024, deadline must be appointed on or before July 1,
2021)
- - Tenure‐track associate professor with a maximum of 3 years in this position (for Jan. 15, 2024, deadline must be appointed on or after July 1,
2021)
- • Adjunct or acting positions are not eligible
- • Applicants are expected to commit a minimum of 80% of their time to conducting research
- • CRI has no citizenship restrictions, and research supported by the award may be conducted at medical schools and research centers in the United States or abroad
Overview: The CRI Lloyd J. Old STAR Program—Scientists Taking Risks—provides long‐term funding to mid‐career scientists, giving them the freedom and flexibility to pursue high‐risk, high‐reward research at the forefront of discovery and innovation in cancer immunotherapy. Because the funds are not restricted to a particular project, the award allows the recipients to follow new and promising lines of investigation, which often lead to unanticipated scientific breakthroughs. The profile of a recipient investigator would be a scientist who takes risks with the expectation of high rewards, even in the face of potential failure. They will use their expertise, scientific acumen and visionary curiosity to ask important, significant and often non‐obvious immunological questions. They will be the rare researcher who connects disparate pieces of discoveries, often from multiple disciplines, to develop and test new hypotheses that lead to step changes in our understanding and innovation to the field of cancer immunotherapy.
It is expected that their discoveries in basic or translational research will ultimately influence the development of new immune‐based therapies that will be effective for more cancer patients. CRI Lloyd J. Old STARs will be at the forefront of discovery and innovation and will be viewed as the leaders in scientific thought and invention.
Additional Resources
Listed below are some quick ways to find external funding opportunities through search mechanisms and announcement listservs.
Additional Resources
- For detailed information on funding opportunities, search www.grants.gov with keywords related to your research interests.
- National Institutes of Health (NIH)
- NIH Career Development Awards (K-Series)
- Patient-Centered Outcomes Research Institute (PCORI)
- Health Resources and Services Administration (HRSA)
- National Science Foundation (NSF)
- North Carolina Biotechnology Center